Rejoyn Therapy App for Depression Approved by the FDA

Was Rejoyn Approved or Cleared by the FDA?

Although news headlines frequently describe Rejoyn as “FDA-approved,” the more accurate regulatory term is FDA-cleared. The FDA granted Rejoyn marketing clearance through the 510(k) pathway under reference number K231209.

Approval and clearance are related but technically different. FDA approval is commonly associated with new drugs and certain high-risk medical devices. A 510(k) clearance means the FDA determined that a medical device is substantially equivalent to an existing legally marketed device while meeting applicable safety, performance, labeling, and software requirements.

Rejoyn is classified as a Class II computerized behavioral therapy device for psychiatric disorders. In everyday language, it is software that delivers an evidence-based therapeutic intervention and is regulated as a medical device rather than as an ordinary wellness app.

The distinction is important for accuracy, but it does not erase the significance of the decision. Rejoyn remains the first FDA-cleared prescription app intended to reduce major depressive disorder symptoms as an adjunctive treatment.

What Is the Rejoyn Therapy App?

Rejoyn, previously known during development as CT-152, is a smartphone-based prescription digital therapeutic created by Click Therapeutics and commercialized in the United States by Otsuka Precision Health.

The six-week program combines three primary components:

• Emotional Faces Memory Task brain-training exercises
• Short lessons based on cognitive behavioral therapy principles
• Reminders and supportive messages designed to encourage participation

Users complete 18 cognitive-emotional exercises and 18 therapeutic lessons during the active treatment period. After those six weeks, lesson materials remain available for an additional four-week extension period, although no new brain-training exercises are introduced.

Unlike a general mental health app, Rejoyn cannot simply be downloaded and activated by anyone curious enough to give it a spin. A licensed healthcare provider must prescribe it, after which the patient receives digital access to the program.

Who Is Rejoyn Intended For?

The FDA-cleared indication is specific. Rejoyn is intended for adults who:

• Are 22 years of age or older
• Have been diagnosed with major depressive disorder
• Are taking antidepressant medication
• Are receiving clinician-managed outpatient care
• Need additional help reducing persistent depression symptoms

The clearance does not cover people younger than 22, individuals using the app without professional care, or patients hoping to replace medication with a digital program. A provider must decide whether the treatment is appropriate based on the patient’s diagnosis, current medication, symptoms, medical history, and overall treatment plan.

How Does Rejoyn Work?

Rejoyn is designed around the idea that depression involves more than neurotransmitters alone. Research has also identified differences in the communication between brain systems involved in emotion processing, attention, memory, and cognitive control.

The app’s developers hypothesize that repeatedly activating these systems together may strengthen a person’s ability to regulate emotional information. This process draws on neuroplasticitythe brain’s capacity to adapt through repeated experience and practice.

The Emotional Faces Memory Task

The signature feature of Rejoyn is the Emotional Faces Memory Task, or EFMT. During an exercise, users view faces displaying emotions such as happiness, sadness, anger, fear, disgust, or surprise. They must remember emotional information from previous images and determine whether it matches what appears next.

The task combines working memory with emotional recognition. Remembering earlier expressions engages cognitive-control networks, while processing facial emotions activates regions involved in emotional response. The goal is to train these systems to work together more effectively.

The task becomes more challenging as the user progresses. It is less like scrolling through inspirational quotes and more like giving the brain a structured workout. Fortunately, no gym membership, protein shaker, or suspiciously enthusiastic personal trainer is required.

CBT-Based Therapeutic Lessons

Rejoyn also delivers brief lessons informed by cognitive behavioral therapy. CBT helps people recognize connections among thoughts, emotions, and behaviors while practicing healthier ways to respond to difficult situations.

The app’s lessons are shorter and more standardized than traditional psychotherapy sessions. They may introduce skills involving emotional awareness, thought patterns, behavioral activation, coping strategies, and the practical application of therapeutic concepts.

However, these lessons do not make Rejoyn a replacement for full psychotherapy. A therapist can explore personal history, relationships, trauma, changing circumstances, and complicated emotions in ways that a predetermined digital program cannot.

What Did the MIRAI Clinical Trial Find?

FDA clearance was supported by the MIRAI study, a phase 3, multicenter, randomized, blinded, sham-controlled trial. The study enrolled 386 adults between ages 22 and 64 who had major depressive disorder and an inadequate response to a stable antidepressant medication.

Participants continued their medication and were randomly assigned to use either Rejoyn or a control app. The control app included a working-memory activity with emotionally neutral material, allowing researchers to compare Rejoyn against more than simply “doing nothing.” Both groups received engagement messages and completed the study remotely.

Primary Depression Rating Results

The primary outcome measured changes on the Montgomery-Åsberg Depression Rating Scale, commonly called MADRS. Lower scores indicate fewer or less severe depressive symptoms.

In the prespecified primary analysis involving 354 participants who completed at least one treatment session and one follow-up assessment, MADRS scores decreased by an average of 9.03 points in the Rejoyn group and 7.25 points in the sham group. The 1.78-point difference favored Rejoyn but narrowly missed the study’s predetermined threshold for statistical significance.

A supportive analysis that included all 386 randomized participants found an average reduction of 8.78 points with Rejoyn and 6.66 points with the sham app. That 2.12-point difference was statistically significant.

This is where sensible interpretation matters. Rejoyn users improved, but control-app users improved substantially too. The difference between groups was modest, and the primary analysis did not technically meet its statistical target. The findings are encouraging, not a digital miracle delivered with push notifications.

Additional Measures and Response Rates

Results on additional patient- and clinician-rated measures generally favored Rejoyn. These included the nine-item Patient Health Questionnaire and the Clinical Global Impression-Severity scale.

In an intent-to-treat analysis, 51.3% of Rejoyn participants achieved at least a 30% reduction in MADRS scores, compared with 38.7% of control participants. Full response, defined as a reduction of at least 50%, occurred in 30.4% of the Rejoyn group and 20.2% of the control group.

Remission rates were 18.2% with Rejoyn and 13% with the sham app. That remission difference was not statistically significant. Response and remission findings were exploratory, so they should not be treated as guaranteed probabilities for an individual patient.

Safety Findings

No treatment-emergent adverse event was judged by investigators to have been caused by Rejoyn. There were no deaths, treatment-related serious adverse events, or discontinuations attributed to the app during the trial.

That favorable safety profile is one of the treatment’s appealing features. Because Rejoyn is software rather than a medication, it does not add the typical pharmacologic concerns associated with another prescription drug, such as metabolic effects or direct drug interactions.

However, participants still experienced events associated with depression and ordinary health conditions. Clinically important suicidality was reported in both the Rejoyn and sham groups. The app itself does not monitor symptoms, determine whether a patient is deteriorating, or automatically alert a prescriber.

Benefits of an FDA-Cleared Depression App

Convenient Treatment Between Appointments

Rejoyn can be used at home and does not require travel to a clinic for every activity. This may make structured therapeutic exercises easier to fit between medical or therapy appointments.

No Additional Medication

Some patients have lingering symptoms but are hesitant to add another drug because of side effects, cost, interactions, or previous experiences. Rejoyn gives clinicians a nonpharmacologic adjunct to discuss while leaving existing treatment in place.

A Standardized Six-Week Program

The intervention follows a defined schedule instead of presenting an endless library of videos and exercises. That structure may be helpful for users who prefer a clear starting point, regular assignments, and an actual finish line.

Clinical Evidence and Regulatory Oversight

Thousands of mental health apps make ambitious promises with limited supporting evidence. Rejoyn has undergone software validation, regulatory review, and controlled clinical testing. That does not mean it works for everyone, but it places the app in a different category from unregulated wellness products.

Limitations Patients Should Understand

Rejoyn may be a useful tool, but the word “app” can create unrealistic expectations. It does not diagnose depression, select medication, conduct a suicide-risk assessment, provide emergency support, or replace regular communication with a healthcare professional.

Other limitations include:

• The FDA-cleared population is limited to adults age 22 and older who are already taking antidepressant medication.
• Clinical benefits were modest compared with the sham app.
• The primary efficacy analysis narrowly missed statistical significance.
• Long-term effectiveness beyond the studied follow-up period remains uncertain.
• Real-world participation may be lower than adherence observed in a monitored clinical trial.
• Cost, insurance coverage, smartphone compatibility, and digital access may create barriers.
• Some people dislike screen-based treatment or may find repeated cognitive exercises frustrating.

Privacy is another reasonable consideration. Before using any prescription digital therapeutic, patients should review what information is collected, how it is stored, whether it is shared with service providers, and what controls are available.

How to Get a Rejoyn Prescription

A patient may discuss Rejoyn with a primary care clinician, psychiatrist, psychiatric nurse practitioner, or another qualified prescriber. The official service also provides access to a virtual consultation pathway in eligible locations.

Once prescribed, Rejoyn is digitally dispensed and unlocked with an access code. The patient downloads the app on a compatible iOS or Android smartphone and follows the activation instructions.

Pricing and coverage have changed since the initial commercial launch and may continue to change. Patients should verify the current cash price, consultation fee, insurance rules, FSA or HSA eligibility, refund terms, and length of access before purchasing.

Questions to Ask a Healthcare Provider

• Are my remaining symptoms appropriate for an adjunctive digital treatment?
• Should I continue my current antidepressant without changes?
• How will we measure whether Rejoyn is helping?
• When should I schedule a follow-up appointment?
• What should I do if my symptoms worsen?
• Would psychotherapy, a medication adjustment, or another treatment be more suitable?

A Realistic Experience of Using Rejoyn for Six Weeks

The following scenario is a fictional composite created to illustrate a possible user experience. It is not a patient testimonial and does not predict individual results.

Imagine Jordan, a 36-year-old adult who has taken the same antidepressant for several months. The medication has helped with the worst symptoms, but concentration, low motivation, and emotional heaviness still drift through the week like unwanted houseguests who have discovered the good snacks.

Jordan’s clinician recommends Rejoyn as an add-on rather than changing medication immediately. They agree to keep the antidepressant dose stable, complete the six-week program, and schedule a follow-up appointment. They also establish a safety plan because no app should be expected to handle a mental health emergency.

During the first week, Jordan downloads the program and completes the introductory activities. The therapeutic lessons feel manageable because they are brief. The emotional-faces exercise feels stranger. Jordan sees a sequence of expressions and must remember whether the current emotion matches one shown earlier. It resembles a memory game designed by a neuroscientist who has very strong opinions about eyebrows.

The task demands concentration, and Jordan makes plenty of mistakes. That is not necessarily a sign that the treatment is failing. Cognitive exercises are supposed to be challenging enough to engage attention and working memory. The app adjusts the experience rather than handing out gold stars for flawless performance.

By week two, the novelty begins to fade. This is where convenience and motivation collide. Having treatment on a phone makes access easier, but it also places the exercise beside email, social media, weather alerts, and videos of dogs refusing to leave public fountains. Jordan begins completing sessions after breakfast, before the day’s digital noise gathers momentum.

During weeks three and four, Jordan does not experience a cinematic transformation. There is no dramatic soundtrack, no sudden urge to dance through a grocery store, and no notification announcing, “Congratulations, your depression has been deleted.” Instead, Jordan notices smaller changes: recovering from stressful thoughts a little faster, completing neglected chores, and feeling more able to use coping strategies introduced in the lessons.

Those changes could be related to Rejoyn, ongoing medication, expectations, natural symptom variation, improved routine, or several factors working together. In real treatment, improvement rarely arrives wearing a name tag.

One difficult evening, Jordan’s symptoms worsen. Rather than opening Rejoyn and expecting it to notify the clinician, Jordan follows the agreed plan and contacts the care team. This distinction is essential: Rejoyn delivers treatment content, but it does not continuously monitor safety or communicate warning signs to the prescriber.

By the sixth week, Jordan has completed most sessions. The exercises feel easier to fit into daily life, although not necessarily entertaining. At the follow-up visit, the clinician reviews symptoms with a standardized questionnaire and asks about sleep, motivation, concentration, side effects, functioning, and suicidal thoughts.

Jordan’s score has improved, but several symptoms remain. The clinician does not declare the app a cure or a failure. Instead, they consider the size of the change, Jordan’s daily functioning, treatment preferences, and whether other adjustments are needed.

This fictional experience captures the most realistic role for Rejoyn: a structured tool that may contribute to gradual improvement when used consistently within a broader treatment plan. For some people, it may provide meaningful additional relief. Others may notice little benefit or struggle to stay engaged. The useful question is not whether an app can “beat depression” by itself, but whether this particular intervention adds enough value to an individual patient’s ongoing care.

Conclusion: A New Tool, Not a Replacement for Care

Rejoyn represents an important development in digital mental health. It is the first FDA-cleared prescription digital therapeutic for reducing major depressive disorder symptoms in adults age 22 and older who are taking antidepressant medication and receiving clinician-managed outpatient care.

Its combination of emotional working-memory exercises, CBT-based lessons, and structured reminders offers a treatment approach that differs from both medication and traditional psychotherapy. Clinical research found symptom improvement and a favorable safety profile, although the advantage over the sham app was modest and the study’s primary analysis narrowly missed statistical significance.

The best way to understand Rejoyn is as another tool in the depression-treatment toolbox. It may extend treatment into daily life without adding another medication, but it cannot replace professional monitoring, emergency care, psychotherapy, or individualized medical decisions.

For patients whose antidepressant has helped but has not provided enough relief, a conversation about Rejoyn may be reasonable. The decision should be made with a qualified healthcare provider, realistic expectations, a follow-up plan, and the understanding that even sophisticated software cannot ask all the questions a caring clinician can.

SEO Metadata